RIPK3-a predictive marker for personalized immunotherapy?

ABSTRACT: Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells. This proposes RIPK3 as a novel predictive marker for personalization of cancer immunotherapy.

SUBMITTER: Smola S 

PROVIDER: S-EPMC4839344 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature